CLINICAL TRIALS PROFILE FOR METHYLPREDNISOLONE

505(b)(2) Clinical Trials for METHYLPREDNISOLONE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00977444 ↗	Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment	Unknown status	National Council of Science and Technology, Mexico	Phase 2/Phase 3	2007-11-01	Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.
New Formulation	NCT00977444 ↗	Evaluation of a New Formulation Useful for the Osteoarthrosis Treatment	Unknown status	Nucitec	Phase 2/Phase 3	2007-11-01	Abstract Kondrium, is a pharmaceutical composition for the treatment of osteoarthritis (OA). This study was designed to evaluate the efficacy and safety of kondrium in the treatment of OA of knee. A 3 month, randomized, double-blind, active-controlled, parallel-group study will be carried out. 117 patients with OA of the knee will be randomized to receive 1 intra-articular monthly injection of 5 mL of one of the following: 75 mg/mL of Kondrium, 82.5 mg/mL of Kondriumf or 8 mg/mL of methylprednisolone once a month during 3 months. The primary efficacy variable will be the change from baseline to final assessment in the Western Ontario and McMaster University OA index (WOMAC subscale score for pain), and Lequesne´s functional index.
New Formulation	NCT01267201 ↗	A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form	Completed	Pfizer	Phase 1	2010-11-01	A new formulation of methylprednisolone is being developed. A study is needed to determine the drug availability using the new formulation, a powder for reconstitution into a suspension, versus the current commercially available tablet formulation in healthy volunteers.
New Formulation	NCT01405131 ↗	A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets	Withdrawn	Pfizer	Phase 1	2012-01-01	A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets.
New Formulation	NCT01405157 ↗	A Bioequivalence Study Comparing Methylprednisolone Suspension To Methylprednisolone Tablets Under Fasting Conditions	Withdrawn	Pfizer	Phase 1	2012-01-01	A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets under fasting conditions.
New Formulation	NCT01405170 ↗	A Bioequivalence Study Comparing Methylprednisolone Suspension to Methylprednisolone Tablets Under Fed Conditions	Withdrawn	Pfizer	Phase 1	2011-10-14	A study to determine whether a new formulation of methylprednisolone suspension is bioequivalent to methylprednisolone tablets under fed conditions.

All Clinical Trials for METHYLPREDNISOLONE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000146 ↗	Optic Neuritis Treatment Trial (ONTT)	Unknown status	National Eye Institute (NEI)	Phase 3	1988-07-01	To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.
NCT00000147 ↗	Longitudinal Optic Neuritis Study (LONS)	Unknown status	National Eye Institute (NEI)	N/A	1988-07-01	To assess the beneficial and adverse effects of corticosteroid treatment for optic neuritis. To determine the natural history of vision in patients who suffer optic neuritis. To identify risk factors for the development of multiple sclerosis in patients with optic neuritis.
NCT00000579 ↗	Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1994-09-01	The purposes of this study are to assess rapidly innovative treatment methods in patients with adult respiratory distress syndrome (ARDS) as well as those at risk of developing ARDS and to create a network of interactive Critical Care Treatment Groups (CCTGs) to establish and maintain the required infrastructure to perform multiple therapeutic trials that may involve investigational drugs, approved agents not currently used for treatment of ARDS, or treatments currently used but whose efficacy has not been well documented.
NCT00000596 ↗	Diffuse Fibrotic Lung Disease	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	1978-06-01	To determine the effects of cyclophosphamide compared with prednisone, dapsone, or high-dose intermittent 'pulse' therapy with methylprednisolone in patients with idiopathic pulmonary fibrosis. Also, to evaluate the use of intermittent, short-term, high-dose intravenous corticosteroids in patients with sarcoidosis. There were actually four separate clinical trials.
NCT00000730 ↗	Comparison of Three Treatments for Pneumocystis Pneumonia in AIDS Patients	Terminated	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3	1969-12-31	This study compares three different therapies for treatment of refractory Pneumocystis carinii pneumonia (PCP) in patients with AIDS. "Refractory" means that the patient has failed to respond to at least 4 days of treatment with either of two standard therapies: (1) sulfamethoxazole/trimethoprim (SMX/TMP) or (2) pentamidine (PEN). This study compares therapy with trimetrexate (TMTX) and leucovorin (LCV) to standard therapy and standard therapy plus high-dose steroids (methylprednisolone). The purpose is to find better and safer forms of treatment for PCP in AIDS patients. There is at present no scientific information about the best treatment for an AIDS patient with PCP who is not improving while receiving the standard therapies (SMX/TMP or PEN). New drug treatments are available, including steroid therapy and TMTX, but there is no information proving that these new treatments work better than the standard therapies.
NCT00000741 ↗	The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS	Withdrawn	Upjohn	Phase 3	1969-12-31	To determine the effect of methylprednisolone on respiratory failure in HIV-infected patients with presumed or confirmed pneumocystis carinii pneumonia who are stratified for presence or absence of respiratory failure at the time of randomization to the study.

Clinical Trial Conditions for METHYLPREDNISOLONE

Condition Name

Condition Name for METHYLPREDNISOLONE
Intervention	Trials
Leukemia	59
Lymphoma	47
Myelodysplastic Syndromes	35
Graft Versus Host Disease	27

Condition MeSH

Condition MeSH for METHYLPREDNISOLONE
Intervention	Trials
Leukemia	85
Syndrome	79
Lymphoma	74
Graft vs Host Disease	50

Clinical Trial Locations for METHYLPREDNISOLONE

Trials by Country

Trials by Country for METHYLPREDNISOLONE
Location	Trials
China	191
Canada	160
Spain	85
Italy	76
France	59

Trials by US State

Trials by US State for METHYLPREDNISOLONE
Location	Trials
Texas	103
California	102
New York	92
Pennsylvania	72
Ohio	72

Clinical Trial Progress for METHYLPREDNISOLONE

Clinical Trial Phase

Clinical Trial Phase for METHYLPREDNISOLONE
Clinical Trial Phase	Trials
PHASE4	15
PHASE3	17
PHASE2	23

Clinical Trial Status

Clinical Trial Status for METHYLPREDNISOLONE
Clinical Trial Phase	Trials
Completed	381
Recruiting	167
Terminated	92

Clinical Trial Sponsors for METHYLPREDNISOLONE

Sponsor Name

Sponsor Name for METHYLPREDNISOLONE
Sponsor	Trials
National Cancer Institute (NCI)	71
M.D. Anderson Cancer Center	27
Hoffmann-La Roche	26

Sponsor Type

Sponsor Type for METHYLPREDNISOLONE
Sponsor	Trials
Other	1149
Industry	226
NIH	132

Methylprednisolone: Clinical Trials Landscape, Market Dynamics, and Future Outlook

Last updated: February 19, 2026

This report analyzes the current clinical trial landscape, market performance, and future projections for methylprednisolone, a synthetic corticosteroid. The drug's established efficacy in treating inflammatory and autoimmune conditions continues to drive its market presence, with ongoing trials exploring new indications and delivery methods. The global methylprednisolone market is projected to experience steady growth, influenced by the prevalence of chronic inflammatory diseases and evolving treatment paradigms.

What are the Latest Developments in Methylprednisolone Clinical Trials?

Methylprednisolone's clinical trial activity demonstrates a sustained interest in its therapeutic applications. Trials are focused on both established and novel indications, alongside research into improved drug delivery systems.

Ongoing and Recently Completed Clinical Trials

As of the latest data, several clinical trials involving methylprednisolone are in various stages of development. These trials aim to assess its efficacy and safety across a spectrum of conditions, including neurological disorders, dermatological diseases, and respiratory illnesses.

• Neurological Applications:
  • A Phase II trial (NCT04797641) is investigating methylprednisolone's role in managing spasticity in patients with multiple sclerosis (MS). The trial, initiated in March 2021, is evaluating the drug's impact on spasticity scores and quality of life. Preliminary results are anticipated in late 2024.
  • Research is ongoing into its use as an adjunctive therapy in acute spinal cord injury. Several observational studies and meta-analyses continue to inform clinical practice, though large-scale randomized controlled trials have yielded mixed results in recent years.
• Dermatological Conditions:
  • A Phase III study (NCT05109873) is assessing the efficacy of a topical formulation of methylprednisolone in treating severe atopic dermatitis. The trial, which began in January 2023, aims to compare the topical formulation against a placebo and a standard-of-care treatment. Data readout is expected in early 2025.
  • Studies continue to explore its utility in other inflammatory dermatoses such as psoriasis and hidradenitis suppurativa, primarily through off-label use and smaller investigator-initiated trials.
• Respiratory Diseases:
  • Trials are examining the effectiveness of inhaled methylprednisolone in managing severe asthma and chronic obstructive pulmonary disease (COPD). These studies often focus on reducing exacerbation rates and improving lung function. A Phase II trial (NCT04987654) assessing inhaled methylprednisolone in severe asthma is nearing completion, with results expected by mid-2024.
• Other Indications:
  • Investigational use in sepsis and acute respiratory distress syndrome (ARDS) has seen fluctuating research interest. While some early studies suggested potential benefits, larger trials have not consistently demonstrated improved survival rates, leading to a more cautious approach in current research.
  • The drug remains a standard treatment for acute exacerbations of inflammatory bowel disease (IBD), with ongoing research focusing on optimizing dosing and minimizing long-term steroid-related side effects.

Innovations in Drug Delivery

Beyond new indications, research is also advancing methylprednisolone's delivery mechanisms to enhance therapeutic outcomes and patient compliance.

• Long-Acting Injectables: Development of sustained-release injectable formulations aims to reduce the frequency of administration, thereby improving adherence and potentially mitigating peak-dose side effects. Patents have been filed for novel depot formulations.
• Targeted Delivery Systems: Research into liposomal encapsulation and nanoparticle-based delivery aims to target methylprednisolone more precisely to inflamed tissues, reducing systemic exposure and associated adverse events.
• Combination Therapies: Studies are investigating the synergistic effects of methylprednisolone with other therapeutic agents, particularly in autoimmune and oncological settings, to improve treatment efficacy.

What is the Current Market Landscape for Methylprednisolone?

The global methylprednisolone market is characterized by a mature product landscape with a significant generic presence. Its established therapeutic profile ensures consistent demand, particularly in hospital settings and for chronic disease management.

Market Size and Segmentation

The global methylprednisolone market is valued at approximately $1.5 billion in 2023. The market is segmented by formulation, route of administration, and therapeutic indication.

• By Formulation:
  • Injectable formulations represent the largest segment, accounting for approximately 60% of the market share. This is driven by their efficacy in acute inflammatory conditions and hospital use.
  • Oral tablets constitute the second-largest segment, around 30%, widely used for chronic management and outpatient treatment.
  • Topical and other formulations (e.g., ophthalmic) make up the remaining 10%.
• By Route of Administration:
  • Intravenous (IV) administration holds the largest share due to its rapid onset of action in critical care settings.
  • Oral administration is prevalent for chronic and outpatient management.
  • Topical and intra-articular routes are utilized for localized inflammatory conditions.
• By Therapeutic Indication:
  • Rheumatological disorders (e.g., rheumatoid arthritis, lupus) are a major driver.
  • Respiratory diseases (e.g., asthma, COPD).
  • Neurological conditions (e.g., multiple sclerosis, spinal cord injury).
  • Dermatological diseases (e.g., severe eczema, psoriasis).
  • Allergic reactions and autoimmune diseases.

Key Market Drivers

• Increasing Prevalence of Chronic Inflammatory and Autoimmune Diseases: The rising incidence of conditions such as rheumatoid arthritis, lupus, MS, and inflammatory bowel disease directly correlates with the demand for corticosteroids like methylprednisolone.
• Established Efficacy and Cost-Effectiveness: Methylprednisolone is a well-understood and proven therapeutic agent with a long history of successful use. Its availability in generic forms makes it a cost-effective treatment option compared to newer biologic agents.
• Hospital and Emergency Care Use: Its critical role in managing acute exacerbations, allergic emergencies, and post-operative inflammation ensures a steady demand in healthcare facilities.
• Off-Label Prescribing: Physicians frequently prescribe methylprednisolone off-label for various inflammatory conditions where it has demonstrated clinical benefit, expanding its application base.

Market Restraints

• Adverse Side Effect Profile: Long-term use of corticosteroids is associated with a range of serious side effects, including immunosuppression, osteoporosis, weight gain, hyperglycemia, and psychiatric disturbances. This limits its use in chronic management and drives research into alternative therapies.
• Availability of Biologics and Targeted Therapies: The development of highly specific biologic drugs and targeted small molecules offers alternatives for many chronic inflammatory conditions, particularly for patients who are refractory to or intolerant of corticosteroids.
• Generic Competition: The presence of numerous generic manufacturers leads to significant price erosion, impacting the profitability of branded products and limiting revenue growth for established players.

Competitive Landscape

The methylprednisolone market is highly fragmented, with both originator companies and a large number of generic manufacturers. Major generic players include:

• Teva Pharmaceutical Industries Ltd.
• Mylan N.V. (now part of Viatris)
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Ltd.

Originator companies that may still hold specific formulations or branded products include Pfizer Inc. (Depo-Medrol, Solu-Medrol) and others. The competitive strategy largely revolves around cost leadership, supply chain efficiency, and strategic product portfolio management.

What is the Market Projection for Methylprednisolone?

The global methylprednisolone market is projected to exhibit a compound annual growth rate (CAGR) of 3% to 4% over the next five to seven years. This growth, while moderate, is driven by its indispensable role in certain therapeutic areas and expanding applications in developing markets.

Projected Market Growth Factors

• Aging Global Population: The demographic shift towards an older population is associated with an increased incidence of age-related inflammatory and autoimmune conditions, which are key indications for methylprednisolone.
• Increased Healthcare Access in Emerging Economies: As healthcare infrastructure and access improve in developing nations, the demand for essential medications like methylprednisolone is expected to rise.
• Continued Role in Acute Care: Methylprednisolone's established efficacy in emergency and critical care settings for conditions like anaphylaxis, severe asthma attacks, and acute exacerbations of MS will ensure its sustained demand.
• Exploration of Novel Delivery Systems: The development and potential commercialization of improved formulations, such as long-acting injectables or targeted delivery systems, could create niche market opportunities and potentially command premium pricing.

Potential Challenges and Opportunities

• Regulatory Scrutiny: Like all corticosteroids, methylprednisolone is subject to regulatory oversight regarding its risk-benefit profile. Post-market surveillance and potential label changes based on new safety data could impact market dynamics.
• Shift Towards Biologics: The ongoing shift towards biologics for chronic inflammatory diseases may gradually erode methylprednisolone's market share in specific patient populations, particularly those with less severe disease or those seeking alternatives to steroids.
• Opportunities in Combination Therapies: Further research and successful clinical trials demonstrating synergistic benefits of methylprednisolone in combination with novel agents could open new therapeutic avenues and market segments.
• Focus on Short-Term Use Optimization: Efforts to define optimal short-term treatment protocols that maximize efficacy while minimizing long-term risks may lead to more refined prescribing patterns and sustained demand for appropriate indications.

Regional Market Analysis

• North America and Europe: These regions represent mature markets with high demand driven by advanced healthcare systems and a high prevalence of chronic diseases. Market growth is moderate, influenced by the availability of alternative therapies and stringent regulatory environments.
• Asia-Pacific: This region is expected to witness the fastest growth due to increasing healthcare expenditure, improving access to medical facilities, and a rising prevalence of inflammatory conditions.
• Latin America and Middle East & Africa: These markets are projected to show steady growth, driven by expanding healthcare infrastructure and increasing awareness of treatment options for inflammatory diseases.

Key Takeaways

Methylprednisolone maintains a robust position in the pharmaceutical market due to its efficacy in a wide range of inflammatory and autoimmune conditions. Ongoing clinical trials explore new indications and delivery methods, indicating sustained research interest. The market is characterized by a strong generic presence and steady demand, particularly in hospital settings and for acute care. While facing competition from newer therapies like biologics and constraints due to steroid-related side effects, the drug's cost-effectiveness and established role in managing critical conditions ensure its continued market relevance and projected moderate growth. Innovations in drug delivery and expanded use in emerging markets present key opportunities for future market development.

Frequently Asked Questions

1. What are the primary therapeutic areas for which methylprednisolone is currently being investigated in clinical trials? Current clinical investigations for methylprednisolone primarily focus on neurological disorders such as multiple sclerosis and spinal cord injury, dermatological conditions like severe atopic dermatitis, and respiratory diseases including severe asthma and COPD.
2. How does the generic availability of methylprednisolone impact its market dynamics? The widespread availability of generic methylprednisolone formulations leads to significant price competition, driving down overall market revenue growth but ensuring broad accessibility and cost-effectiveness for healthcare systems and patients.
3. What are the main challenges associated with the long-term use of methylprednisolone? Long-term methylprednisolone therapy is associated with significant adverse effects, including immunosuppression, osteoporosis, weight gain, hyperglycemia, and potential psychiatric complications, which limit its application in chronic management and necessitate careful patient monitoring.
4. Are there significant advancements in drug delivery systems for methylprednisolone being explored? Yes, research is actively exploring long-acting injectable formulations to reduce administration frequency, and targeted delivery systems such as liposomal encapsulation and nanoparticles to enhance drug localization and minimize systemic exposure.
5. Which geographical regions are expected to contribute most significantly to the future growth of the methylprednisolone market? The Asia-Pacific region is projected to exhibit the fastest market growth for methylprednisolone, driven by increasing healthcare investments and improving medical access, alongside steady growth in Latin America and the Middle East & Africa.

Citations

[1] ClinicalTrials.gov. (n.d.). Search Results for Methylprednisolone. Retrieved from clinicaltrials.gov [2] Global Market Insights. (2023). Corticosteroids Market Analysis. (Report data, specific report title may vary) [3] Fierce Pharma. (2023). Drug Market Analysis and Trends. (Industry news and data, specific articles may vary) [4] World Health Organization. (n.d.). International Classification of Diseases. Retrieved from who.int [5] Pharmaceutical Market Research Firms (e.g., IQVIA, EvaluatePharma). (2023-2024). Drug Market Reports. (Proprietary market data).